Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage

Genes Chromosomes and Cancer

Volumn 40, Issue 4, 2004, Pages 342-348

  Partheen, Karolina ^a   Levan, Kristina ^a   Österberg, Lovisa ^a   Helou, Khalil ^a   Horvath, György ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FEMALE; GENETIC ANALYSIS; GENETIC SCREENING; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; OUTCOMES RESEARCH; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; CYTOGENETIC ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMANS; KARYOTYPING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3142615822     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20053     Document Type: Article

References (30)

1. Alcock HE. Stephenson TJ, Royds JA, Hammond DW. 2003. Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization. Genes Chromosomes Cancer 37:369-380.
2. Anbazhagan R, Fujii H, Gabrielson E. 1998. Allelic loss of chromosomal arm 8p in breast cancer progression. Am J Pathol 152:815-819.
3. Andcrsson H, Friberg LG, Horvath G, Johansson O, Akesson M, Westberg R. 1995. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study. Acta Oncol 34:821-827.
4. Arnold N, Hagele L, Walz L, Schempp W, Pfisterer J, Bauknecht T, Kiechle M. 1996. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosomes Cancer 16:46-54.
5. Berck JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parnar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg PH, et al. 1999. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10(Suppl 1):87-92.
6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. 2002. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259.
7. Chu LW, Troncoso P, Johnston DA, Liang JC. 2003. Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 36:303-312.
8. Covens AL. 2000. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78:269-274.
9. Fox H. 1998. Pathology of ovarian Cancer. In: Kavanagh JJ, Singletary SE, Einhorn N, DelPetrillo AD, editors. Cancer in women. Oxford, UK: Blackwell Science; p 415-442.
10. Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC, Wigler MH. 2002. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99:13647-13652.
11. Hauptmann S, Denkert C, Koch I, Petersen S, Schluns K, Reles A, Dietel M, Petersen I. 2002. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 33:632-641.
12. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S. 2001. Carcinoma of the ovary. J Epidemiol Biostat 6:107-138.
13. Holschneider CH, Berek JS. 2000. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3-10.
14. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM. 1999. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 96:3928-3933.
15. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman V, Pinkel D. 1992. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
16. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D. 1994. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10:231-243.
17. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N. 2001. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 91:534-540.
18. Lassus H, Laitinen MP, Anttonen M, Heikinheimo M, Aaltonen LA, Ritvos O, Butzow R. 2001. Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4. Lab Invest 81:517-526.
19. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. 2001. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413:311-316.
20. Polakis P. 1997. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1332:F127-147.
21. Pribill I, Speiser P, Leary J, Leodolter S, Hacker NF, Friedlander ML, Birnbaum D, Zeillinger R, Krainer M. 2001. High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genet Cytogenet 129:23-29.
22. Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, Ayhan A, Wells D, Fishman A, Gore M, DiCioccio RA, Piver MS, Whittemore AS, Ponder BA, Gayther SA. 2003. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 63:417-423.
23. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF. 2002. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8:3324-3331.
24. Risinger JI, Berchuck A, Kohler MF, Boyd J. 1994. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 7:98-102.
25. Runnebaum IB, Stickeler E. 2001. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 127:73-79.
26. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, Jr., James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. 2001. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 61:5895-5904.
27. Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, Yakushiji M, Testa JR. 1997. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 20:320-328.
28. Suzuki S, Moore DH, 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. 2000. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60:5382-5385.
29. Tapper J, Butzow R, Wahlstrom T, Seppala M, Knuutila S. 1997. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 75:1782-1787.
30. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. 2003. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:885-891.